- Home
- KALV vs CTO Comparison
KALV vs CTO Comparison
Compare KALV & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- CTO
- Stock Information
- Founded
- KALV N/A
- CTO 1902
- Country
- KALV United States
- CTO United States
- Employees
- KALV N/A
- CTO N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- CTO Real Estate Investment Trusts
- Sector
- KALV Health Care
- CTO Real Estate
- Exchange
- KALV Nasdaq
- CTO Nasdaq
- Market Cap
- KALV 563.1M
- CTO 592.0M
- IPO Year
- KALV N/A
- CTO N/A
- Fundamental
- Price
- KALV $12.00
- CTO $18.14
- Analyst Decision
- KALV Strong Buy
- CTO Strong Buy
- Analyst Count
- KALV 8
- CTO 3
- Target Price
- KALV $24.83
- CTO $23.00
- AVG Volume (30 Days)
- KALV 729.1K
- CTO 343.8K
- Earning Date
- KALV 03-12-2025
- CTO 05-01-2025
- Dividend Yield
- KALV N/A
- CTO 8.45%
- EPS Growth
- KALV N/A
- CTO N/A
- EPS
- KALV N/A
- CTO N/A
- Revenue
- KALV N/A
- CTO $124,519,000.00
- Revenue This Year
- KALV N/A
- CTO $18.87
- Revenue Next Year
- KALV N/A
- CTO $9.15
- P/E Ratio
- KALV N/A
- CTO N/A
- Revenue Growth
- KALV N/A
- CTO 14.11
- 52 Week Low
- KALV $7.30
- CTO $16.12
- 52 Week High
- KALV $15.50
- CTO $21.15
- Technical
- Relative Strength Index (RSI)
- KALV 55.34
- CTO 46.49
- Support Level
- KALV $11.42
- CTO $16.76
- Resistance Level
- KALV $12.35
- CTO $19.50
- Average True Range (ATR)
- KALV 0.96
- CTO 0.63
- MACD
- KALV 0.04
- CTO 0.00
- Stochastic Oscillator
- KALV 88.74
- CTO 58.89
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.